Fig. 1 · Structure

Documents & Downloads

Tenofovir

Cat. No. A10908 CAS 147127-20-6

HIV reverse transcriptase inhibitor

Tenofovir is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV in the blood.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Reverse transcriptase

Cellular Effect

Cell Line Activity Value Description Reference
Bone marrow cell CC50 3.5 μM Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay [PMID: 20439609]
Bone marrow cell CC50 4.7 μM Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay [PMID: 20439609]
C3H/3T3 EC50 0.23 μM Inhibition of murine sarcoma virus-induced transformation of mouse embryo fibroblast C3H/3T3 cells after 6 days [PMID: 18556209]
C8166 EC50 7.1 μM Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus type 2 ROD infected in C8166 cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis [PMID: 21803462]
CCRF-CEM CC50 > 100 μM Cytotoxicity against human CEM cells assessed as cell count after 3 days [PMID: 26513643]
CCRF-CEM CC50 > 250 μM Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 72 hrs by coulter counter analysis [PMID: 21429755]
CCRF-CEM EC50 3.2 μM Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis [PMID: 21429755]
CCRF-CEM EC50 3.7 μM Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis [PMID: 26513643]
CCRF-CEM EC50 3.7 μM Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay [PMID: 25617695]
CCRF-CEM EC50 3.7 μM Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis [PMID: 24686012]
CCRF-CEM EC50 3.9 μM Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis [PMID: 26513643]
CCRF-CEM EC50 3.9 μM Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay [PMID: 25617695]
CCRF-CEM EC50 3.9 μM Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis [PMID: 24686012]
CCRF-CEM EC50 4.1 μM Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus 1 3B infected in CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis [PMID: 21803462]
CCRF-CEM EC50 4.6 μM Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis [PMID: 21429755]
CCRF-CEM IC50 6.9 μM Cytostatic activity against human CEM cells after 72 hrs by coulter counting analysis [PMID: 24686012]
CHO CC50 173 μM Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay [PMID: 19001108]
CHO CC50 21 μM Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay [PMID: 19001108]
CHO CC50 435 μM Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay [PMID: 19001108]

19 records · Scroll to view more

Tenofovir Research Summary

This section summarizes 2 in vitro studies of Tenofovir from 1 published reference. In vitro models include HK-2 cells.

Tenofovir In Vitro Studies

In HK-2 cells, Tenofovir diminished cell viability beginning at 24 h and continuing for 72 h compared with vehicle control. ATP levels were unchanged after 24 or 48 h incubation but diminished at all tested Tenofovir concentrations at 72 h compared with vehicle. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Tenofovir reduces HK-2 cell viability

Cell-based study · HK-2 cells [1]

HK-2 cells were treated with Tenofovir, and viability was assessed using Trypan Blue Exclusion. Tenofovir diminished cell viability beginning at 24 h and continuing for 72 h compared with vehicle control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viability in HK-2 cells using Trypan Blue ExclusionReported result 1.5, 3.0, 4.75, 14.5, or 28.8 μM TFV: TFV diminished cell viability beginning at 24 h and continuing for 72 h when compared to vehicle control.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1.5, 3.0, 4.75, 14.5, or 28.8 μM
Exposure duration
24, 48, or 72 h
Method
cells were treated
Vehicle
phosphate buffered saline (PBS)
Co-treatment
Other interventions in this design: bovine pituitary extract 50 μg/mL; recombinant epithelial growth factor 5 ng/mL. Compound effect isolated by the comparison: when compared to vehicle control.
Methods and source locations

Compound reported in the paper: Tenofovir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. TFV Effects on Cell Viability (S5); 4. Materials and Methods > 4.2. Cell Lines and Tenofovir (TFV) Treatment (S38, S41, S42); 4. Materials and Methods > 4.3. Cell Viability (S49); Figure 2 legend (S93)

cell viability in HK-2 cells using Trypan Blue Exclusion: cell viability in HK-2 cells using Trypan Blue Exclusion; comparator: vehicle control — 2. Results > 2.1. TFV Effects on Cell Viability (S5); 4. Materials and Methods > 4.2. Cell Lines and Tenofovir (TFV) Treatment (S41); Figure 2 legend (S93)

Tenofovir reduces ATP levels after prolonged exposure in HK-2 cells

Cell-based study · HK-2 cells [1]

HK-2 cells were treated with Tenofovir or PBS vehicle. ATP levels were unchanged after 24 or 48 h but diminished at all tested concentrations after 72 h compared with vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ATP levelsReported result ATP levels were unchanged compared to vehicle by TFV after 24 or 48 h incubation. ATP levels were diminished by all concentrations of TFV at 72 h when compared to vehicle (p < 0.001).[1]

Literature-Reported Treatment Conditions

Treatment concentration
1.5, 3.0, 4.75, 14.5, or 28.8 μM
Exposure duration
24, 48, or 72 h
Method
cells were treated
Vehicle
phosphate buffered saline (PBS)
Co-treatment
Other interventions in this design: bovine pituitary extract 50 μg/mL; recombinant epithelial growth factor 5 ng/mL. Compound effect isolated by the comparison: when compared to vehicle.
Methods and source locations

Compound reported in the paper: Tenofovir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.2. TFV Effects on Mitochondrial Function (S11, S12); 4. Materials and Methods > 4.2. Cell Lines and Tenofovir (TFV) Treatment (S38, S41, S42); 4. Materials and Methods > 4.4. ATP Measurement (S51, S54); Figure 3 legend (S97)

ATP levels: ATP levels; comparator: vehicle — 2. Results > 2.2. TFV Effects on Mitochondrial Function (S11, S12); 4. Materials and Methods > 4.4. ATP Measurement (S51)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 147127-20-6
Applications HIV reverse transcriptase inhibitor
Formula C9H14N5O4P
Molecular Weight 287.2
Synonyms Viread
SMILES
C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(=O)(O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 4 mg/mL (13.92 mM)
Water 2 mg/mL (6.96 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tenofovir Research References

  1. [1] Murphy RA, Stafford RM, Petrasovits BA, et al. Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity. Int J Mol Sci (2017). PMID: 28257038 DOI: 10.3390/ijms18030531 Source material

Added to your cart

View Cart Checkout
Loading...